Featured Research

from universities, journals, and other organizations

Snakebites a public health problem in Africa

Date:
September 10, 2011
Source:
Institut de Recherche pour le Développement (IRD)
Summary:
One and a half million people per year are poisoned by snake venom in Sub-Saharan Africa. An IRD researcher recently analysed around 100 surveys and medical reports published over the past 40 years. No large-scale study of the situation had hitherto been conducted and public health authorities had underestimated the size of the problem. This means that currently only 10% of victims are treated, owing to a shortage of antivenoms* and lack of awareness among health care practitioners. Yet the clinical complications can be very serious, even fatal. A bite from a cobra or mamba can bring on death by asphyxia --- due to respiratory paralysis --- within 6 hours of the incident. Venom injected by the ocellated carpet viper, common in the African savannah, can cause hemorrhages leading to the victim's death in a few days. This new study provides authorities with more detailed and reliable figures which should enable them to readjust their health-care services in better tune with needs.

King cobra. A bite from a cobra or mamba can bring on death by asphyxia -- due to respiratory paralysis -- within 6 hours of the incident.
Credit: © Heiko Kiera / Fotolia

One and a half million people per year are poisoned by snake venom in Sub-Saharan Africa. An IRD researcher recently analysed around 100 surveys and medical reports published over the past 40 years. No large-scale study of the situation had hitherto been conducted and public health authorities had underestimated the size of the problem. This means that currently only 10% of victims are treated, owing to a shortage of antivenoms* and lack of awareness among health care practitioners. Yet the clinical complications can be very serious, even fatal. A bite from a cobra or mamba can bring on death by asphyxia -- due to respiratory paralysis -- within 6 hours of the incident. Venom injected by the ocellated carpet viper, common in the African savannah, can cause hemorrhages leading to the victim's death in a few days.

Related Articles


This new study provides authorities with more detailed and reliable figures which should enable them to readjust their health-care services in better tune with needs.

For snakes the best form of defence is attack. Some show complete ruthlessness when they sense they are under threat. They all have their methods. The Gaboon viper, for example, injects its venom very deep into the muscles with its 5 cm long fangs. The spitting cobra blinds its victims with its venom. And although only one out of two snake bites is venomous, these reptiles are still a real danger for humans. The number of incidents is considerable, especially in Sub-Saharan Africa where they represent a sizeable public health hazard, though neglected by the health authorities.

One and a half million envenomings

Every year over 300 000 people living South of the Sahara have to be treated after a snakebite, as the IRD researcher has shown. However, many cases are not reported, given the difficulty of access to health centres and the frequent reliance on traditional medicine. That figure therefore does not reflect the complete number of envenomings and specialists consider it to represent only between one-third and one-fifth of the real amount. This new study thus indicates up to one and a half million victims per year. Mortality resulting from a bite -probably also underestimated- can reach 7 000 and limb amputations range from 6 000 to over 14 000 per year.

Although many one-off studies have improved estimates, no large-scale survey had hitherto been conducted. Aiming to make up for the gaps, the IRD specialist performed a meta-analysis, a critical review of existing scientific works, taking the representativeness1 and heterogeneity of their results into account. He therefore studied in fine detail 100 or so scientific articles, conference proceedings and clinical reports published between 1970 and 2010. This thorough survey yielded much more reliable figures for the number of patients who were victims of snake bites.

Working in the fields: a high-risk activity

These studies also highlighted the situations most likely to favour biting incidents: 95% of bites occur in rural areas, particularly in plantations. The people most at risk are therefore agricultural workers. And in Africa, agriculture is the main economic activity.

Urban areas are not spared from such incidents either, even if the incidence of bites is from 10 to 20 times lower than in rural settings. In some regions therefore, in the rainy season, envenomings represent over 10% of hospital admissions.

Devastating bites

In the most dangerous African snake species, two types of venom can be distinguished: the neurotoxic venom of the cobras and mambas, and the hemorrhagic and necrotic type of the vipers -including the ocellated carpet viper, the most widespread in the savannah. In other words, the first type causes respiratory paralysis, which can kill the victim by asphyxia between 1 and 6h after the bite. The second induces oedema and necroses in the limbs plus hemorrhage which can prove fatal in just a few days. The effective treatment remains intravenous injection of antivenom as swiftly as possible after the bite, in order to neutralize the toxic substance.

A vicious circle

The availability of these antidotes is currently restricted and only 10% of venomous snake bites are treated. Shortage of data has meant that up to now the problem remained underestimated by the health authorities. Moreover, these remedies are costly and the duration of their effect is short -3 to 5 years- which discourages people from keeping up stock supplies. In such situations, it is difficult to define the budgets and allocate funds for snakebite management and for setting up the necessary schemes for awareness-building among health-care professionals. Without training for such medical personnel in the use of antivenoms, treatment can give disappointing results, subsequently deterring people from using them. These chain reactions reduce demand. Manufacturers then hesitate before producing antivenoms they cannot be sure of selling. In the end this process diminishes their accessibility. The number of doses sold has been divided by ten in Africa since the 1980s, falling from 200 000 per year to less than 20 000 in the early 2000s.

This survey presents some realistic figures for needs in antivenom. The researcher's results indicate the need for an estimated 500 000 doses each year. The health authorities of these countries can now use these data as a basis for improving the quality of health care provided for victims and for organizing a counting and surveillance system.


Story Source:

The above story is based on materials provided by Institut de Recherche pour le Développement (IRD). Note: Materials may be edited for content and length.


Journal Reference:

  1. Jean-Philippe Chippaux. Estimate of the burden of snakebites in sub-Saharan Africa: A meta-analytic approach. Toxicon, 2011; 57 (4): 586 DOI: 10.1016/j.toxicon.2010.12.022

Cite This Page:

Institut de Recherche pour le Développement (IRD). "Snakebites a public health problem in Africa." ScienceDaily. ScienceDaily, 10 September 2011. <www.sciencedaily.com/releases/2011/09/110909111639.htm>.
Institut de Recherche pour le Développement (IRD). (2011, September 10). Snakebites a public health problem in Africa. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2011/09/110909111639.htm
Institut de Recherche pour le Développement (IRD). "Snakebites a public health problem in Africa." ScienceDaily. www.sciencedaily.com/releases/2011/09/110909111639.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins